Epizyme, Inc. (EPZM) Financial Statements (2024 and earlier)

Company Profile

Business Address 400 TECHNOLOGY SQUARE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2022
MRQ
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including: 176,800373,600381,100240,300276,400242,200
Cash and cash equivalents 98,336168,215139,48286,671226,66477,895
Short-term investments 78,454205,391241,605153,63349,775164,297
Other undisclosed cash, cash equivalents, and short-term investments 10(6)13(4)(39)8
Receivables 6,5723,1052,56720,06738223
Other undisclosed current assets 22,67128,38815,51012,1689,0226,449
Total current assets: 206,043405,093399,177272,535285,804248,672
Noncurrent Assets
Operating lease, right-of-use asset 20,05417,30521,206
Property, plant and equipment 1,5452,1522,2192,0572,5273,124
Intangible assets, net (including goodwill) 42,84947,002    
Intangible assets, net (excluding goodwill) 42,84947,002    
Other noncurrent assets 18,5092,0211,9879091,028645
Total noncurrent assets: 82,95768,48025,4122,9663,5553,769
TOTAL ASSETS: 289,000473,573424,589275,501289,359252,441
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 41,04238,73531,33124,48024,55021,001
Accounts payable 10,26510,1638,7824,7807,0014,994
Accrued liabilities 30,77728,57222,54919,70017,54916,007
Debt   3,03916110620
Contract with customer, liability13,300
Other liabilities   16374 
Other undisclosed current liabilities 4,1544,665    
Total current liabilities: 45,19643,40034,38637,83324,66421,621
Noncurrent Liabilities
Long-term debt and lease obligation 18,49715,40919,12053 110
Capital lease obligations53 110
Liabilities, other than long-term debt 11,950213,8444,60629,32429,010
Deferred revenue and credits28,80928,809
Deferred revenue 11,950 3,806
Contract with customer, liability3,806
Other liabilities  2138800515201
Operating lease, liability 18,49715,40919,120
Total noncurrent liabilities: 30,44715,43022,9644,65929,32429,120
Total liabilities: 75,64358,83057,35042,49253,98850,741
Equity
Equity, attributable to parent (20,688)184,897331,137233,009235,371201,700
Preferred stock 36,12736,12737,432   
Common stock 111010876
Additional paid in capital 1,183,0061,137,4701,050,695819,779723,510555,473
Accumulated other comprehensive income (loss) 3319(54)(49)(106)
Accumulated deficit (1,239,835)(988,713)(757,019)(586,724)(488,097)(353,673)
Total equity: (20,688)184,897331,137233,009235,371201,700
Other undisclosed liabilities and equity 234,045229,84636,102   
TOTAL LIABILITIES AND EQUITY: 289,000473,573424,589275,501289,359252,441

Income Statement (P&L) ($ in thousands)

6/30/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues 37,42715,76223,80021,70010,0008,007
Revenue, net10,0008,007
Cost of revenue (10,498)(5,067)    
Gross profit: 26,92910,69523,80021,70010,0008,007
Operating expenses (264,921)(236,111)(200,942)(149,805)(146,842)(119,833)
Operating loss: (237,992)(225,416)(177,142)(128,105)(136,842)(111,826)
Nonoperating income (expense) (13,108)(6,164)6,9054,5322,1971,614
Loss from continuing operations before income taxes: (251,100)(231,580)(170,237)(123,573)(134,645)(110,212)
Income tax expense (benefit) (22)(114)(58)(57)336 
Loss from continuing operations: (251,122)(231,694)(170,295)(123,630)(134,309)(110,212)
Loss before gain (loss) on sale of properties:(251,122)(231,694)(170,295)(123,630)(134,309)(110,212)
Net loss attributable to parent: (251,122)(231,694)(170,295)(123,630)(134,309)(110,212)
Other undisclosed net loss available to common stockholders, basic   (2,940)   
Net loss available to common stockholders, diluted: (251,122)(231,694)(173,235)(123,630)(134,309)(110,212)

Comprehensive Income ($ in thousands)

6/30/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss: (251,122)(231,694)(170,295)(123,630)(134,309)(110,212)
Comprehensive loss: (251,122)(231,694)(170,295)(123,630)(134,309)(110,212)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  (16)73(5)57(106)
Comprehensive loss, net of tax, attributable to parent: (251,122)(231,710)(170,222)(123,635)(134,252)(110,318)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: